Granted Patent
B2
US 12,372,529 · App. 15/922,349 · Granted Jul 29, 2025
Use of CD36 to identify cancer subjects for treatment
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION
G01N33/57492A61K38/1709A61K38/18A61K47/6811C07K5/12C12Q1/6886C12Q2600/106C12Q2600/158G01N2333/70596G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
Claims (2)
1. A method for evaluating a subject's responsiveness to treatment with a Psap peptide, the method comprising: determining a level of CD36 in a sample obtained from a subject having cancer, wherein an elevated level of CD36 in the sample compared to a control level indicates that the subject is responsive to or likely to be responsive to treatment with a Psap peptide, wherein the level of CD36 in the sample is determined by performing an assay, and wherein the method further comprises administering to the subject identified as responsive to or likely to be responsive to treatment with a Psap peptide an effective amount of a Psap peptide to treat the cancer;
wherein the Psap peptide is selected from the group consisting of CDWLPK (SEQ ID NO: 1), DWLPK (SEQ ID NO: 2), and DWLP (SEQ ID NO: 3).
Assignments (2)
LICENSE
Recorded Nov 15, 2024
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 069385/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 6, 2022
From: WATNICK, RANDOLPH S.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 059521/0718 →
Continuity (3)
Division
14773596
Provisional Application
61782850
· Mar 14, 2013
References Cited (82)
US 5696080A
· O'Brien et al.
· 1997
[cited by applicant]
US 5700909A
· O'Brien
· 1997
[cited by applicant]
US 5714459A
· O'Brien et al.
· 1998
[cited by applicant]
US 6500431B1
· Gill
· 2002
[cited by applicant]
US 7166691B2
· Koochekpour et al.
· 2007
[cited by applicant]
US 7341730B1
· Gill
· 2008
[cited by applicant]
US 9921224B2
· Watnick
· 2018
[cited by examiner]
US 20010041343A1
· Pankowsky
· 2001
[cited by applicant]
US 20020177551A1
· Terman
· 2002
[cited by applicant]
US 20040018513A1
· Downing et al.
· 2004
[cited by applicant]
US 20060275274A1
· Onichtchouk et al.
· 2006
[cited by applicant]
US 20070099251A1
· Zhang et al.
· 2007
[cited by applicant]
US 20100144603A1
· Watnick
· 2010
[cited by applicant]
US 20110271357A1
· Kim et al.
· 2011
[cited by applicant]
US 20140113310A9
· Skolnick et al.
· 2014
[cited by applicant]
JP 2005516180A
· 2005
[cited by applicant]
JP 2007127423A
· 2007
[cited by applicant]
JP 2009244146A
· 2009
[cited by applicant]
JP 2013246080A
· 2013
[cited by applicant]
WO WO9503821
· 1995
[cited by applicant]
WO WO9525543
· 1995
[cited by applicant]
WO WO9630332
· 1996
[cited by applicant]
WO WO0002902
· 2000
[cited by applicant]
WO WO0224952
· 2002
[cited by applicant]
WO WO2004084930
· 2004
[cited by applicant]
WO WO2004096159
· 2004
[cited by applicant]
WO WO2005073374
· 2005
[cited by applicant]
WO WO2007047796
· 2007
[cited by applicant]
WO WO2007066018
· 2007
[cited by applicant]
WO WO2009002931
· 2008
[cited by applicant]
WO WO2009002931A2
· 2008
[cited by examiner]
WO WO2010105256
· 2010
[cited by applicant]
WO WO2011084685
· 2011
[cited by applicant]
WO WO2012176138A2
· 2012
[cited by examiner]
WO WO2013096868
· 2013
[cited by applicant]
WO WO2015064594
· 2015
[cited by applicant]
Clezardin et al. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. Mar. 15, 1993;53(6):1421-30. (Year: 1993).
[cited by examiner]
Febbraio et al. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. Sep. 2001;108(6):785-91. (Year: 2001).
[cited by examiner]
Kuemmerle et al. Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation. Mol Cancer Ther 2011;10:427-436. (Year: 2011).
[cited by examiner]
STN CAS Registrysm: Exact and pattern searching of protein sequences. 2008. (Year: 2008).
[cited by examiner]
[No Author Listed], Myc and Human cancer database. John Hopkins University School of medicine & john Hopkins health system. Last updated Apr. 14, 2013. Last accessed at http://www.mycancegene.org/site/cancerDB.asp?PageI…
[cited by applicant]
Akamatsu, et al., “Potent Inhibition of Protein-Tyrosine Phosphatase by Phosphotyrosine-Mimic Containing Cyclic Peptides”, Bioorganic & Medicinal Chemistry, vol. 5, No. 1, pp. 157-163, 1997, Elsevier Science Ltd.
[cited by applicant]
Baselga, “Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer”, The Oncologist 2011;16(suppl 1):12-19, www.TheOncologist.com.
[cited by applicant]
Campana et al., Secretion of prosaposin, a multifunctional protein, by breast cancer cells. Biochim Biophys Acta. May 24, 1999; 1427(3): 392-400.
[cited by applicant]
Clezardin et al. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. Mar. 15, 1993;53(6):1421-30.
[cited by applicant]
Dawson et al., CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. Aug. 11, 1997; 138(3): 707-17.
[cited by applicant]
De Fraipont et al., Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation…
[cited by applicant]
Doll et al., Thrombospondn-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators f angiogenesis in the prostate. Prostate. Dec. 1, 2001; 49(4):293-305.
[cited by applicant]
Febbraio et al. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. Sep. 2001;108(6):785-91.
[cited by applicant]
Genbank Submission; NIH/NCBI, Accession No. EAW54436. Venter et al., Dec. 18, 2006. 3 pages.
[cited by applicant]
Gopalakrishnan et al., Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. Biochem J. Nov. 1, 2004;383(Pt. 3):507-15.
[cited by applicant]
Hu et al., Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol Cancer. Feb. 4, 2010; 9:30.
[cited by applicant]
Kalas et al., Oncogenes and Angiogenesis; down-regulation of thromspondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res. Oct. 1, 2005; 65(19):8878-86.
[cited by applicant]
Kang et al., Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation od stromal p53 and Tsp-1. Proc Natl Acad Sci USA. Jul. 21, 2009; 106(29): 12115-20. Epub Jul. 6, 2009. Erratum in: Proc Natl Acad…
[cited by applicant]
Koochekpour et al., Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer. Dec. 2005; 44(4):351-64.
[cited by applicant]
Koochekpour et al., Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP. J Cell Biochem. Jun. 1, 2007;101(3):631-41.
[cited by applicant]
Koochekpour et al., Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells. J Cell Biochem. Aug. 15, 2008;104(6):2272-85.
[cited by applicant]
Kuemmerle, et al., “Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation”, Mol Cancer Ther; 10(3);427-36, Mar. 2011, AACR, Downloaded from mct.aacrjournals.org on May 17, 2017.
[cited by applicant]
Lee et al., Sasposin C promotes survival and prevents apoptosis via P13K/Akt-dependent pathway in prostate cancer cells. Mol Cancer. Nov. 17, 2004;3:31.
[cited by applicant]
Morimoto et al., Sasposin A: second cerebrosidase activator protein. Proc Natl Acad Sci USA. May 1989; 86(9):3389-93.
[cited by applicant]
O'Brien et al., Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science. Aug. 26, 1988;241(4869):1098-101.
[cited by applicant]
O'Brien et al., Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. Mar. 1, 1991;5(3):301-8.
[cited by applicant]
Panigone et al., Up-regulations of prosaposin by the retinoid HPR and the effect on ceramide production and integrin receptors. FASEB J. Jun. 2001; 15(8):1457-7.
[cited by applicant]
Qi et al., Functional human saposins expressed in
[cited by applicant]
S. Wang et al: 11 Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment 11, Science Translational Medicine, vol. 8, No. 329, Mar. 9, 2016 (Mar. 9, 2016…
[cited by applicant]
Simantov et al. CD36: A Critical Anti-Angiogenic Receptor, Frontiers in Bioscience 8, s874-882, Sep. 1, 2003.
[cited by applicant]
Vogelstein et al., p53: The most frequently altered gene in human cancers. nature education. 2010; 3(9):6. Last accessed at http://www.nature.com/scitable/topicpage/p53-th3-most-frequently-altered-gene-in-14192717 on Ju…
[cited by applicant]
Yabkowitz et al., Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res. Jan. 15, 1993;53(2):378-87.
[cited by applicant]
Koochekpour, PSAP (prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)). Atlas Genet Cytogenet Oncol Haematol. 2007;10:370-384.
[cited by applicant]
Lawler et al., “Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2”, Cold Spring Harb Perspect Med, 2012, 13 pages.
[cited by applicant]
Non-Final Office Action issued in co-pending U.S. Appl. No. 16/549,961 DTD Jul. 2, 2020.
[cited by applicant]
Extended European Search Report on EP Patent Application No. 21171264.1 dated Oct. 6, 2021 (10 pages).
[cited by applicant]